Key Points
- Director Jean Jacques Bienaime bought 400 shares of Ascendis Pharma A/S at $237.80 each, a transaction worth about $95,120, and now owns 400 shares.
- Ascendis Pharma stock was down 1.8% in trading, opening at $235.26, while shares remain near their 52-week high of $250.74.
- Analysts remain bullish on ASND, with a consensus rating of Buy and an average target price of $295.39.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) Director Jean Jacques Bienaime acquired 400 shares of the company's stock in a transaction on Tuesday, May 26th. The stock was acquired at an average price of $237.80 per share, with a total value of $95,120.00. Following the acquisition, the director owned 400 shares in the company, valued at approximately $95,120. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Ascendis Pharma A/S Trading Down 1.8%
NASDAQ ASND opened at $235.26 on Thursday. The stock has a market cap of $14.68 billion, a P/E ratio of 27.13 and a beta of 0.41. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. The stock has a 50 day simple moving average of $233.40 and a two-hundred day simple moving average of $222.79. Ascendis Pharma A/S has a fifty-two week low of $156.56 and a fifty-two week high of $250.74.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of $0.21 by $0.11. The firm had revenue of $285.45 million during the quarter, compared to analysts' expectations of $362.47 million. On average, analysts forecast that Ascendis Pharma A/S will post 11.73 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on ASND shares. Citigroup started coverage on Ascendis Pharma A/S in a research note on Monday, May 18th. They issued a "buy" rating and a $355.00 target price for the company. Oppenheimer raised their target price on Ascendis Pharma A/S from $246.00 to $262.00 and gave the company an "outperform" rating in a research note on Thursday, February 12th. Barclays raised their target price on Ascendis Pharma A/S from $342.00 to $345.00 and gave the company an "overweight" rating in a research note on Monday, May 11th. Wells Fargo & Company lowered their target price on Ascendis Pharma A/S from $330.00 to $326.00 and set an "overweight" rating for the company in a research note on Friday, May 8th. Finally, Wedbush restated an "outperform" rating and issued a $273.00 target price on shares of Ascendis Pharma A/S in a research note on Thursday, April 9th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $295.39.
Read Our Latest Report on ASND
Institutional Trading of Ascendis Pharma A/S
Institutional investors and hedge funds have recently modified their holdings of the business. Advisory Services Network LLC bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth $26,000. Arax Advisory Partners increased its holdings in shares of Ascendis Pharma A/S by 212.2% in the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 104 shares in the last quarter. Leonteq Securities AG bought a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth $36,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth $42,000. Finally, Jones Financial Companies Lllp increased its holdings in shares of Ascendis Pharma A/S by 57.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company's stock worth $44,000 after purchasing an additional 83 shares in the last quarter.
About Ascendis Pharma A/S
(
Get Free Report)
Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.
The company's lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
